树突状细胞疫苗用于肿瘤免疫治疗的挑战及突破  

Challenges and Breakthroughs of DC Vaccines in Tumor Immunotherapy

作　　者：张诗琳 刘恒 杨晓梅 卢小玲[1,2,3] ZHANG Shilin;LIU Heng;YANG Xiaomei;LU Xiaoling(College&Hospital of Stomatology,Guangxi Medical University,Nanning 530021,China;Guangxi Key Laboratory of Nanobody Research,Nanning 530021,China;Guangxi Nanobody Engineering Research Center,Nanning 530021,China;School of Preclinical Medicine,Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学口腔医学院/附属口腔医院,南宁530021 [2]广西纳米抗体研究重点实验室,南宁530021 [3]广西壮族自治区纳米抗体工程研究中心,南宁530021 [4]广西医科大学基础医学院,南宁530021

出　　处：《中国生物工程杂志》2024年第12期64-75,共12页China Biotechnology

基　　金：国家自然科学基金国际(地区)合作与交流项目(82220108003);广西科技基地和人才工程(GuiKe-AD20238062);广西重点研发计划(GuiKe-AAB21196024)资助项目。

摘　　要：树突状细胞(dendritic cell,DC)疫苗是目前肿瘤免疫治疗中具有巨大潜力的手段之一,DC疫苗基于DCs摄取呈递抗原并激活T细胞从而发挥抗肿瘤作用。但传统DC疫苗在治疗实体瘤领域进展缓慢,其障碍就是单核细胞来源的DCs活性限制及肿瘤介导的免疫抑制。与传统DC疫苗治疗相比,新型DC疫苗和DC疫苗联合疗法为改进肿瘤治疗方法提供了新方向。综述了传统DC疫苗在实体瘤治疗领域面临的主要挑战,目前新型DC疫苗的研究进展以及DC疫苗联合治疗策略,展望了其发展前景,为未来DC疫苗在肿瘤治疗方面的研究和产品研发提供了新思路。Currently,one of the most promising tools in tumor immunotherapy is dendritic cell(DC)vaccines.DC vaccines are based on the uptake of antigens delivered by DCs and the activation of T cells to induce anti-tumor effects.However,traditional DC vaccines have made slow progress in the treatment of solid tumors due to the limited activity of monocyte-derived DCs and tumor-mediated immunosuppression.Novel DC vaccines and DC vaccine combination therapies offer new ways to improve tumor treatment compared to traditional DC vaccine therapy.This article reviews the major challenges faced by traditional DC vaccines in the field of solid tumor therapy,the current research progress of novel DC vaccines,and DC vaccine combination therapy strategies.It also discusses their development prospects and provides new ideas for future research and product development of DC vaccines in tumor therapy.

关 键 词：树突状细胞疫苗 肿瘤疫苗 联合治疗 免疫抑制 

分 类 号：Q939.91[生物学—微生物学]